ChromaDex Achieves New Regulatory Milestones in the European Union & Australia

ChromaDex receives authorizations to sell its patented, NAD+ boosting nicotinamide riboside chloride in the European Union and in Australia with market exclusivity

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here